Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Dec 2011

De Pas Tommaso M, Giovannini Monica, Manzotti Michela, Trifirò Giuseppe, Toffalorio Francesca, Catania Chiara, Spaggiari Lorenzo, Labianca Roberto, Barberis Massimo

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Large Cell
Share to Carcinoma, Neuroendocrine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Genes, erbB-1

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 22042963
DOI: 10.1200/JCO.2011.36.2251

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.PMID 22042963Read ↗

BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: a case report and review of the literature.Semantic proximity Read ↗

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.Semantic proximity Read ↗

Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.Semantic proximity Read ↗

EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.Semantic proximity Read ↗

Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung.Semantic proximity Read ↗

BRAF V600E-mutated combined large cell neuroendocrine carcinoma and adenocarcinoma responding to targeted therapy.Semantic proximity Read ↗

ALK Rearrangement in Lung Neuroendocrine Neoplasms: Case Series of Non-Asian Patients With Response to ALK Inhibitors.Semantic proximity Read ↗

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.Semantic proximity Read ↗

Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.Semantic proximity Read ↗

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.Semantic proximity Read ↗

Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.Semantic proximity Read ↗

Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.